Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Lynn Rochester (Newcastle University)
Innovative Medicines Initiative (IMI)

Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with a greater risk of disease, cognitive decline, risk of falls and even earlier death. As the population ages, the number of people experiencing mobility issues is expected to rise. However, accurately assessing people’s mobility, especially in the real world, is far from easy.

MOBILISE-D aims to develop a comprehensive system to analyse people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease (COPD), Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.

The project plans to work closely with regulators and other stakeholders to ensure that the solutions are accepted. Once validated, the MOBILISE-D results will help to improve the accurate assessment of mobility in clinical trials. They will also make it easier for clinicians to monitor patients’ mobility and thereby contribute to improved, more personalised caret


1,597,781 euros (total 24 millions €)

Our Team

ISGlobal Principal Investigator (PI)

  • Judith Garcia
    Judith Garcia Cap del programa de Malalties no transmisibles i medi ambient

ISGlobal Team

Altres projectes

Veure projectes passats


Severe respiratory failure in COVID-19: clinical, biological and imaging risk factors


Valorización de l'Arxiu Europeu del Genoma-Fenoma (EGA) per a la Indústria i la Societat


Cohorte Covid-19 en Cataluña


Exposure to emerging contaminants in drinking water in Barcelona potentially liked to chronic diseases and wellbeing


Las Voces de los Afectados por la Nefropatía Mesoamericana